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Objective.—To review the scope of the problem facing individuals with migraine who are under- or uninsured. In this
first of a 2-part narrative review, we will explore migraine epidemiology and the challenges that face this vulnerable
population.
Background.—Implementation of the Affordable Care Act has improved access to health care for many individuals
who were previously uninsured, but there are many, particularly those of certain demographics, who are at high risk for
worse outcomes.
Methods.—A narrative review was performed after a series of discussions within the Underserved Populations in
Headache Medicine Special Interest Section meetings of the American Headache Society. Literature was reviewed for key
concepts underpinning conceptual boundaries and a broad overview of the subject matter. Published guidelines, state-
specific Medicaid websites, headache quality measurement set, literature review, and expert opinion were used to tailor
suggested treatment options and therapeutic strategies.
Results.—Migraine is common, yet remains underdiagnosed and associated with worse outcomes among those of
under-represented backgrounds and those who are underinsured or uninsured. Low socioeconomics may play an important
role in the disease progression, characteristics, outcome, and quality of life of patients with migraine and other headache
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disorders. Other barriers to optimal care include time constraints, lack of access to specialty providers, transportation, and
financial limitations.
Conclusion.—There are many barriers and challenges that affect people with migraine who are underinsured or unin-
sured, particularly those of under-represented racial backgrounds and of lower socioeconomic status.
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INTRODUCTION
Although the Patient Protection and Affordable
Care Act has improved access to medical insurance,
barriers persist for some patients to receive appro-
priate care. Patient cost-sharing, including higher
deductibles, has left millions underinsured or unin-
sured.1,2 Underinsurance, previously defined as a
lack of needed care or services due to onerous out-
of-pocket patient costs in spite of medical coverage,
varies considerably by state (eg, 19% in California,
31% in Texas).1,3-5 A recent report found that histor-
ically underserved groups (eg, young adults, the
poor, Latinos, blacks) have made significant gains in
health insurance coverage.6 In spite of this, 16% of
19- to 64-year-old adults remain uninsured.1 Vulner-
able populations in health care have been defined to
include patients who are racial or ethnic minorities,
children, elderly, socioeconomically disadvantaged,
underserved, or those with certain medical condi-
tions who are at risk for disparate health care access
and outcomes because of economic, cultural, ethnic,
or health characteristics.7
For many families with health insurance, higher
deductibles have outpaced income growth.8 Thirty-
one million people (23% of 19-64 year olds) with
health insurance were underinsured because of high
deductibles or other patient cost-sharing, and 44%
of these people reported not getting needed care
because of cost. Additionally, 57% of the uninsured
did not seek care because of cost.1
Headache is a leading reason for medical con-
sultation, especially for neurological evaluation.9,10
Tension-type headache and migraine are ranked as
the second and third most common prevalent dis-
orders, respectively, and migraine is the seventh-
highest specific cause of disability worldwide.11
We aimed to provide a narrative review of the
underserved, underinsured adult population with
migraine. We address the epidemiology and chal-
lenges that face this population. We suggest strate-
gies to optimize migraine management in patients
with minimal to no insurance, provide pearls for
counseling patients, review a few high quality low
cost migraine medications, and suggest resources to
help practitioners care for those with little or no
insurance. Other considerations that may be helpful
when caring for this vulnerable population are
explored. This manuscript will be in 2 parts. In this
part (part 1), we will explore migraine epidemiology
and challenges in underserved and some vulnerable
adult populations. In part 2 of this narrative review,
we will explore migraine care strategies and consid-
erations for adult migraine patients in underserved
and vulnerable populations.
METHODS
This narrative review was drafted after a series of
discussions at the Underserved Populations in Head-
ache Medicine Special Interest Section meetings of
the American Headache Society (AHS) meetings, in-
cluding a preliminary review at the 2014 AHS Scotts-
dale Headache Symposium, a detailed point-by-point
discussion at the 2015 AHS Annual Scientific Meeting
in Washington, District of Columbia, and a section
meeting at the 2016 AHS Annual Scientific Meeting
in San Diego, California, for finalization. Conceptual
strategies and discussions were also made via telecon-
ferencing and email correspondence. The discussions
explicitly addressed subject content, reviewed organi-
zational strategies, and details. PubMed, Scopus, and
Google Scholar databases were utilized. Search terms
included terms such as “underinsured population in
migraine,” “underserved population in migraine,”
“low socioeconomic status migraine,” “migraine
underinsured,” “underserved opioids migraine,”
“vulnerable population opioids migraine,”
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“underserved treatment migraine,” “underinsured
treatment migraine,” and “Affordable Care Act
migraine.” Literature was reviewed for key concepts
underpinning conceptual boundaries and a broad
overview of the subject matter. Published guidelines,
headache quality measurement set, literature review,
and expert opinion were used to tailor suggested
treatment options and therapeutic strategies included
in this narrative review. State-specific Medicaid web-
sites were reviewed between 2014 and 2016 for speci-
fied medication costs. The manuscript was drafted
and revised by a subcommittee of AHS Special Inter-
est Section members (manuscript authors) over this
timeframe.
BACKGROUND
Migraine Epidemiology in Underserved Popula-
tions.—Socioeconomic Status.—A low socioeco-
nomic status has been posited to impact the presence,
onset, and worsening of migraine in the population. A
large US population-based study12 confirmed that
migraine prevalence is strongly associated with annual
household income, with a 60% higher rate of
migraine in lower (<$10,000) vs higher (>$30,000)
income groups. Although disability was not related to
income, attack frequency was higher in lower income
groups. The more recent American Migraine Preva-
lence and Prevention (AMPP) study confirmed this
finding in both men and women.13 For those with an
annual household income >$90,000, migraine preva-
lence was 13.6% in women and 4.2% in men, but in
those with an annual household income <$22,500,
prevalence was much higher at 20.1% in women and
8.8% in men. In adjusted analyses, a household
income >$90,000 reduced the risk by almost 50%.
The AMPP study also addressed the impact of
socioeconomic status on migraine prevalence in
adolescents, an age group where biological predis-
position likely predominates.14 Household income
did not impact migraine prevalence in adolescents
with a family history of migraine. However, adoles-
cents without a family history featured a migraine
prevalence that increased as household income
decreased.
This finding in adolescents supported the social
causation hypothesis, where factors that are
associated with low socioeconomic status elevate
disease prevalence, as opposed to the social selec-
tion hypothesis, where disease disability secondarily
leads to a decline in socioeconomic status because
of impacted educational and occupational function-
ing.14 The social causation hypothesis was further
tested in the AMPP study, where an observed
higher migraine prevalence in those with lower
household income was largely driven by a higher
migraine incidence rather than any disparity in
migraine remission rates.15 These findings suggest
that migraine onset is strongly driven by exogenous
factors that would be more prominent in those with
low socioeconomic status, such as physical and psy-
chological stress, abuse, and neglect.
Low socioeconomic status may also influence
migraine attack frequency and progression from
episodic to chronic migraine. Although household
income is an unexplored risk factor for chronic mi-
graine onset, those with a less than high school educa-
tion had a greater than threefold risk of chronic daily
headache (CDH) in comparison to those with a grad-
uate school education in a population-based sample.16
In addition, the odds of CDH remission were nearly
one-fifth in those with less than a high school educa-
tion in comparison to those with a graduate school
education. Data from the National Health Interview
survey show that the unemployed or part time
employed population is more likely to report head-
aches than full time workers. Migraine prevalence
was higher in the lower income group and varied with
insurance status.17 The uninsured and individuals with
Medicaid were more likely to report migraine than
individuals with commercial insurance.
Racial Groups.—A recent review of available data
from national survey studies addressed dis-
crepancies in prevalence and care for migraine in
different racial groups.18 Migraine prevalence is
highest in Native Americans, then whites, follow-
ed by African Americans, Hispanics, and Asian
Americans. Average prevalence of severe headache
or migraine from the National Health Interview
Survey 2005 to 2012 data was 17.7% for Native
Americans, 15.5% for whites, 14.5% for Hispanics,
14.45% for blacks, and 9.2% for Asians.18 How-
ever, studies rarely distinguish between subgroups
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within ethnicities, such as Chinese, Japanese, and
Korean within US Asians. African Americans and
Hispanics have a disproportionately low number of
outpatient visits and specific migraine diagnostic
rates in comparison to generic headache
diagnoses.18
Barriers to Care in the Population.—Barriers to
migraine care have been addressed in a population-
based study using the AMPP. Barriers were divided
into 3 levels: medical consultation, diagnosis, and use
of appropriate therapies. Only 45.5% of those with
migraine consulted a health care professional in the
previous year, and 86.7% of those were diagnosed
with migraine.19 Only 66.7% were using migraine-
specific therapies. In total, only 26.3% of those with
migraine traversed all 3 barriers to care. Having
health insurance was associated with a nearly 2-fold
increase in receiving a migraine diagnosis, and a high
annual household income was the strongest predictor
of using appropriate migraine-specific therapy.
Related, ineffective acute treatment of episodic
migraine is associated with new onset chronic
migraine, and as treatment efficacy diminishes, the
proportion of subjects with an annual household
income of <$50,000 escalates.20 A low socioeco-
nomic status is also associated with increased utiliza-
tion of the emergency department (ED) for
headache care in the US population.21 Compared to
those with an annual household income of >$90,000,
those with an annual household income of <$22,500
in the previous year had a 2.4-fold higher rate of ED
use (at least 1 visit) and a 11.5-fold higher rate of fre-
quent ED use (at least 4 visits).21
Challenges to Headache Care Among Those on
Medicaid, Underinsured, or Uninsured.—There are
several challenges to headache care among those on
Medicaid, underinsured, or uninsured. One study,
which analyzed 11 years of data from the National
Ambulatory Medical Care Survey and National Hos-
pital Ambulatory Medical Care Survey from 1997 to
2007, showed that the uninsured and those with
Medicaid receive substandard therapy for migraine,
at least in part because they received less care in
physicians’ offices and more care in EDs.22 Transpor-
tation to specialized headache care centers poses a
problem as headache clinics are few, and in some
states headache specialty centers do not exist.23 Indi-
viduals with lower incomes may not have the time,
financial, social, or other resources for coordinated
headache care, especially if it includes long-distance
travel or an inpatient headache stay (childrearing,
work loss, etc).24 One study found disparities among
low income or uninsured subjects in that they were
less likely to receive triptans, a migraine-specific
abortive care.25 One study in Germany, where virtu-
ally everyone has health insurance and drug cover-
age, suggested that disparities exist in the use of new
and recommended migraine drug treatments by
insurance status, although confirmatory studies in
the United States are needed.26 This discrepancy
may be particularly important as ineffective acute
treatment is associated with new onset chronic
migraine.20 A recent study has also explored the
issue of triptan specific coverage, using New York
state as an example in an examination of 100 drug
formularies. The coverage of generic and brand
name triptans by both commercial and noncommer-
cial insurers was very heterogeneous, although
generic sumatriptan, naratriptan, zolmitriptan, and
rizatriptan were covered by nearly all plans. The
study demonstrated that equitable access was prob-
lematic, particularly for specific triptans and formu-
lations, quantity limits, and requirements for step
therapy that may be major barriers to care impacting
patients specifically with government (noncommer-
cial) insurance plans.27 The efficacy and cost effec-
tiveness of treatment for, as well as health care
utilization by, individuals with a low socioeconomic/
educational status and migraine should be further
explored.
Important risk factors for migraine progression
may be specifically problematic among people with
low educational and income levels that have inade-
quate insurance. Medication overuse is a common
risk factor for migraine progression, and individuals
with migraine and a low socioeconomic status may
be particularly at risk for developing medication
overuse headache.28 Anxiety and depression are
risk factors for migraine progression and contri-
bute to migraine-related disability and impact.29
Underserved populations may also have limitations
in access to psychiatric care as well as
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pharmacological interventions. A multidisciplinary
treatment approach with behavioral management
including psychology or biofeedback may be useful,
but it is often not covered as a part of basic insur-
ance coverage (Medicaid, etc) and may be too
expensive when paid out of pocket.
CONCLUSIONS
Migraine is an extraordinarily common, dis-
abling neurological disorder in the population, but
people with under-represented backgrounds and
poor health insurance coverage have lower diagnos-
tic rates and worse outcomes. Low socioeconomics
may play an important role in the disease progres-
sion, characteristics, outcome, and quality of life of
patients with migraine and other headache disor-
ders. Other barriers to optimal care include time
constraints, lack of access to specialty providers
treating both migraine and its comorbidities, ther-
apy coverage, transportation, and financial limita-
tions. In part two of this narrative review, we will
address management considerations and provide
potential strategies to optimize migraine care in
patients who are underinsured or uninsured.
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